Head-to-head · WeighScore
Care Bare Rx vs Nucific
The verdict
Care Bare Rx takes it — 75/100 to 56.2/100.
Care Bare Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Care Bare Rx | Nucific |
|---|---|---|
| WeighScore | 75/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #43 | #417 |
| Semaglutide | From $199/mo (shared weight-loss price) | Not disclosed |
| Tirzepatide | From $199/mo (shared weight-loss price) | Not disclosed |
| Coverage | Multi-state | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #43 · C
Strengths
- Oral tirzepatide as well as injectable — rare on this board
- Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
- LegitScript certified and HIPAA compliant
- One platform if you also want hair, TRT, sexual health or NAD+
Where it loses points
- The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
- Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
- No named clinicians, founding year or parent company disclosed
- Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.